Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration

START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...

Related Keywords

Andrew Cutler ,Sanjeev Sharma ,Eric Hughes ,Yael Ashman ,Drug Administration ,Psych Congress Elevate ,Neuroscience Education Institute ,Teva Pharmaceuticals ,Subcutaneous Administration Olanzapine For ,Teva Pharmaceutical Industries Ltd ,Teva Pharmaceutical Industries ,Executive Vice President ,Chief Medical Officer ,Clinical Global Impression ,Patient Global Impression ,Associate Clinical Professor ,Medical University ,Neuroscience Education ,Sample Titration Kit ,Poster Presentations ,Real World Effectiveness ,Deutetrabenazine When Initiated Using ,Week Patient Titration Kit ,Interim Results ,Patient Satisfaction With ,Patient Titration Kit ,Population Estimate ,Patients With Tardive Dyskinesia ,Real World Clinical Practice ,Across Age Groups ,Underlying Psychiatric Conditions ,Payer Types ,Healthcare Professional Perspectives ,Key Impacts ,Tardive Dyskinesia ,Long Acting Subcutaneous Antipsychotic ,Local Tolerability ,Injection Site Reactions ,Long Term Safety ,Patients With Schizophrenia ,Double Blind Study ,Placebo Controlled Trial Assessing Safety ,Subcutaneous Administration ,Extended Release Injectable Suspension Use ,Adults With Schizophrenia ,Patient Characteristics ,Transitioning Patients ,Long Acting Injectable Antipsychotics ,Hypothetical Case ,Initiating Long Acting Injectable Antipsychotics ,Release Tablets ,Adverse Events ,Malignant Syndrome ,Melanin Containing Tissues ,Adverse Reactions ,Prescribing Information ,Motor Impairment ,